Furthermore, we chose to use WT1-CTLs as WT1 is the most extensively studied pMHC target in AML, demonstrating efficacy against a broad repertoire of primary patient samples in vitro as well as both safety and efficacy in human clinical trials [11, 12]. The gene discussed is WT1; the disease is acute myeloid leukemia.